Entera Bio (ENTX) Receivables - Other (2017 - 2018)
Entera Bio (ENTX) recorded quarterly Receivables - Other of $836000.0 in Q4 2018, up 359.34% on a QoQ basis from $182000.0 in Q4 2017, and up 359.34% year-over-year from $182000.0 in Q4 2017.
Entera Bio (ENTX) Receivables - Other (2017 - 2018) Analysis & Trends
Entera Bio has disclosed Receivables - Other across 2 years of filings, most recently posting $836000.0 for Q4 2018.
- Quarterly Receivables - Other rose 359.34% year-over-year to $836000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $836000.0 (up 359.34% YoY) and the FY2018 annual result came in at $836000.0, up 359.34% from the prior year.
- Receivables - Other climbed to $836000.0 in Q4 2018, from $182000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $836000.0 in Q4 2018 and troughed at $182000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 836,000.00 |
| Dec 31, 2018 | 836,000.00 |
| Dec 31, 2017 | 182,000.00 |
| Dec 31, 2017 | 182,000.00 |